by Raynovich Rod | Aug 28, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals, Macro
But Uncertainty Clouds Intermediate Term Economic Outlook: Oil prices, Emerging Markets, Russia and the FED Concerns about another Middle East war and a spike in oil prices waned a bit today but many “undertoads” remain such as weak economic data, taper...
by Raynovich Rod | Aug 26, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Life science stocks resumed their upward trajectory today with major ETFs (FBT,IBB,XBI) up over 2% and a green screen for the sector. Mid-cap biopharma stocks are strong once again. The IBB hit an August low of $187 on August 19 after a high in early August near $201....
by Raynovich Rod | Aug 22, 2013 | Macro
Update 8/26 Best idea on securities exchanges: Randall W.Forsyth in his Barron’s Up and Down Wall Street column recommends that the NASDAQ and NYSE are put under the watchful eye of the NSA. And while we are on “big data” there is news that Amazon...
by Raynovich Rod | Aug 21, 2013 | Biopharmaceuticals, Macro
Very Strange Whipsaw Day Who is in charge of this market, humans or computers? Earlier: My biopharma screen has gone green. Maybe “taper light” scenario means buy biotech as macro and interest rates are not affected. More later but NASDAQ reversal...
by Raynovich Rod | Aug 20, 2013 | 2024 Rayno Tools and Diagnostics Portfolio
Diagnostics Company Stocks Are Off Their 2013 Highs Life science tools and diagnostics stocks are near all time highs despite stretched valuations because of a strong secular biotech bull market and perceived synergy with biopharmaceuticals. Key themes are point of...
by Raynovich Rod | Aug 18, 2013 | Biopharmaceuticals, Macro
Tempering, Tapering and Transition A mild sell-off shifted momentum to the bears last week as countercurrents and seasonality comes into play. Heavy vacations in August transition to Labor Day weekend, Jewish holidays then a pick up in trading by mid-September. Here...
by Raynovich Rod | Aug 15, 2013 | Biopharmaceuticals, Macro
Biotech Sector Momentum Quits-IBB at Support Level of $189 NASDAQ Off 1.73% to 3605 Have fund managers raised cash and gone on vacation? Moreover many weaker sectors have become leaders like gold, silver,materials and energy. Walmart and Cisco are leading the way...
by Raynovich Rod | Aug 13, 2013 | Biopharmaceuticals
Market Can’t Stay Down in Quiet Trading After a couple of lackluster trading days the market perked up as economic news continues positive with retail sales up for the fourth consecutive month and many analysts believing Europe is coming out of recession. And...
by Raynovich Rod | Aug 8, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Intrexon (XON), a synthetic biology Company, focused in healthcare, animal science and agriculture raised over $160M in a Huge IPO . CEO Randall Kirk purchased 30M shares. Some pundits say this event punctuates the “golden age of biology”. This is the...
by Raynovich Rod | Aug 7, 2013 | Clinical Diagnostics and Tools
The 2013 AACC (American Association for Clinical Chemistry) Meeting was attended by 650 exhibitors and over 17,000 professionals all looking to connect in the In Vitro Diagnostics (IVD) industry. For a complete up-to-date news and analysis of the industry check...